Recombinant influenza vaccines — Competitive Intelligence Brief

Recombinant influenza vaccines (Recombinant influenza vaccines) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vaccine. Area: Immunology / Infectious Disease.

marketed Vaccine Influenza hemagglutinin (HA) and neuraminidase (NA) antigens Immunology / Infectious Disease Biologic

Target snapshot

Recombinant influenza vaccines (Recombinant influenza vaccines) — Henry M. Jackson Foundation for the Advancement of Military Medicine. Recombinant influenza vaccines stimulate the immune system to produce antibodies and cellular immunity against influenza virus antigens produced through recombinant DNA technology.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Recombinant influenza vaccines TARGET	Recombinant influenza vaccines	Henry M. Jackson Foundation for the Advancement of Military Medicine	marketed	Vaccine	Influenza hemagglutinin (HA) and neuraminidase (NA) antigens
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
Mumps vaccine	Mumps vaccine	Sinovac (Dalian) Vaccine Technology Co., Ltd.	marketed	Live attenuated vaccine	Mumps virus surface antigens
EV71 Vaccine only	EV71 Vaccine only	Sinovac Biotech Co., Ltd	marketed	Inactivated viral vaccine	Enterovirus 71 (EV71) viral antigens
Rabivax-S	Rabivax-S	University of Oxford	marketed	Rabies vaccine	Rabies virus glycoprotein
mRNA-1273	mRNA-1273	Assistance Publique - Hôpitaux de Paris	marketed	mRNA vaccine	SARS-CoV-2 spike protein (S protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
• 2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Vaccine class)

1. GlaxoSmithKline · 16 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 12 drugs in this class
3. Pfizer · 6 drugs in this class
4. International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
5. Henogen · 3 drugs in this class
6. Pfizer Inc. · 2 drugs in this class
7. Sanofi · 2 drugs in this class
8. Jiangsu Province Centers for Disease Control and Prevention · 2 drugs in this class
9. BioNTech · 2 drugs in this class
10. Merck Sharp & Dohme LLC · 2 drugs in this class